Literature DB >> 16336951

Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.

GuiFu Wu1, Jincai Luo, Jamal S Rana, Roger Laham, Frank W Sellke, Jian Li.   

Abstract

OBJECTIVE: Cyclooxygenase-2 (COX-2) is induced by hypoxic stimuli and is also involved in the process of angiogenesis. We previously demonstrated that vascular endothelial growth factor (VEGF) is one of the principal factors produced by hypoxic myocytes and is responsible for the induction of COX-2 expression in endothelial cells. Yet the signaling pathways by which VEGF modulates COX-2 gene expression are still less well defined. We therefore examined the regulation of VEGF-induced COX-2 expression by the mitogen-activated protein kinase (MAPK) family in endothelial cells. METHODS AND
RESULTS: Human umbilical vascular endothelial cells (HUVECs) were incubated with U0126 (ERK1/2 inhibitor, 10 microM), SB203580 (p38 inhibitor, 20 microM), and SP600125 (JNK inhibitor, 20 microM), as well as the COX-2 selective inhibitor, NS398, for 1 h before treating with VEGF (20 ng/ml). COX-2 expression induced by VEGF at both mRNA and protein levels was significantly inhibited by selective p38 and JNK inhibitors but not by the ERK1/2 inhibitor. The phosphorylation of p38 and JNK kinases was observed as early as 5 min in HUVECs after VEGF stimulation. Furthermore, the biological significance of the COX-2 gene in endothelial cells was examined by over-expressing or knocking down COX-2 gene expression. (3)H-Thymidine incorporation and Matrigel techniques were used to determine cell proliferation and vascular structure formation. VEGF-induced cell proliferation was significantly reduced when HUVECs were either pre-treated with NS398 (21.52+/-3.6%) or transfected with COX-2 siRNA (34.12+/-5.81%). In contrast, in HUVECs with over-expression of COX-2, VEGF-induced cell proliferation was increased 42.56+/-7.69%. Moreover, the formation of vascular structure assayed by Matrigel demonstrated that VEGF-induced vascular structure formation was accelerated in COX-2 over-expressing cells but attenuated in COX-2 siRNA-transfected cells.
CONCLUSION: COX-2 plays an important role in VEGF-induced angiogenesis via p38 and JNK kinase activation pathways. These findings suggest that the cardioprotective role of COX-2 may be, at least in part, through its angiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336951     DOI: 10.1016/j.cardiores.2005.09.019

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  68 in total

1.  Fluid Flow Regulation of Revascularization and Cellular Organization in a Bioengineered Liver Platform.

Authors:  Pedro M Baptista; Emma C Moran; Dipen Vyas; Maria H Ribeiro; Anthony Atala; Jessica L Sparks; Shay Soker
Journal:  Tissue Eng Part C Methods       Date:  2016-02-17       Impact factor: 3.056

Review 2.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

3.  Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses.

Authors:  Rongqin Ren; Peter C Charles; Chunlian Zhang; Yaxu Wu; Hong Wang; Cam Patterson
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  Sustained inhibition of neovascularization in vldlr-/- mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF-κB pathway.

Authors:  Xue Cai; Sudipta Seal; James F McGinnis
Journal:  Biomaterials       Date:  2013-10-18       Impact factor: 12.479

5.  COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.

Authors:  Emma Bell; Frida Ponthan; Claire Whitworth; Deborah A Tweddle; John Lunec; Christopher P F Redfern
Journal:  Clin Exp Metastasis       Date:  2014-05-25       Impact factor: 5.150

6.  Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Authors:  Guodong Zhang; Dipak Panigrahy; Sung Hee Hwang; Jun Yang; Lisa M Mahakian; Hiromi I Wettersten; Jun-Yan Liu; Yanru Wang; Elizabeth S Ingham; Sarah Tam; Mark W Kieran; Robert H Weiss; Katherine W Ferrara; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

7.  Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.

Authors:  Ji-Young Kim; Seung Woo Chung; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2015-01-15       Impact factor: 4.200

8.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

9.  Antidicer RNAse activity of monocyte chemotactic protein-induced protein-1 is critical for inducing angiogenesis.

Authors:  Arpita Roy; Miaojun Zhang; Yasser Saad; Pappachan E Kolattukudy
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-18       Impact factor: 4.249

10.  Inhibition of phorbol ester-induced mouse skin tumor promotion and COX-2 expression by celecoxib: C/EBP as a potential molecular target.

Authors:  Kyung-Soo Chun; Joydeb Kumar Kundu; Kwang-Kyun Park; Won-Yoon Chung; Young-Joon Surh
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.